File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1517/13543784.17.10.1581
- Scopus: eid_2-s2.0-52949101763
- PMID: 18808318
- WOS: WOS:000260080000016
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: LB80380: A promising new drug for the treatment of chronic Hepatitis B
Title | LB80380: A promising new drug for the treatment of chronic Hepatitis B |
---|---|
Authors | |
Keywords | Chronic hepatitis B therapy LB80380 Nucleotide analogue Resistance Viral suppression |
Issue Date | 2008 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eid |
Citation | Expert Opinion On Investigational Drugs, 2008, v. 17 n. 10, p. 1581-1588 How to Cite? |
Abstract | Hepatitis B virus is a significant cause of liver cirrhosis and hepatocellular carcinoma in patients with chronic infection. Higher levels of viral load are associated with increased risk of developing liver-related complications. The current available oral therapies suppress viral replication through their action on the hepatitis B virus polymerase. As treatment with oral nucleoside/nucleotide analogues is associated with the development of drug-resistant mutations, there is continuing research for newer and more potent antiviral agents to reduce the chance of drug resistance. LB80380, a prodrug, is an oral nucleotide analogue that inhibits viral replication by incorporation into the viral DNA. Antiviral activity against wild-type virus and virus with drug-resistant mutations was demonstrated in Phase II trials, with significant reduction of viral load in patients treated with LB80380. LB80380 was also shown to be safe and well tolerated. © 2008 Informa UK Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/163205 |
ISSN | 2023 Impact Factor: 4.9 2023 SCImago Journal Rankings: 1.414 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, J | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Yuen, MF | en_US |
dc.date.accessioned | 2012-09-05T05:28:44Z | - |
dc.date.available | 2012-09-05T05:28:44Z | - |
dc.date.issued | 2008 | en_US |
dc.identifier.citation | Expert Opinion On Investigational Drugs, 2008, v. 17 n. 10, p. 1581-1588 | en_US |
dc.identifier.issn | 1354-3784 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163205 | - |
dc.description.abstract | Hepatitis B virus is a significant cause of liver cirrhosis and hepatocellular carcinoma in patients with chronic infection. Higher levels of viral load are associated with increased risk of developing liver-related complications. The current available oral therapies suppress viral replication through their action on the hepatitis B virus polymerase. As treatment with oral nucleoside/nucleotide analogues is associated with the development of drug-resistant mutations, there is continuing research for newer and more potent antiviral agents to reduce the chance of drug resistance. LB80380, a prodrug, is an oral nucleotide analogue that inhibits viral replication by incorporation into the viral DNA. Antiviral activity against wild-type virus and virus with drug-resistant mutations was demonstrated in Phase II trials, with significant reduction of viral load in patients treated with LB80380. LB80380 was also shown to be safe and well tolerated. © 2008 Informa UK Ltd. | en_US |
dc.language | eng | en_US |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eid | en_US |
dc.relation.ispartof | Expert Opinion on Investigational Drugs | en_US |
dc.subject | Chronic hepatitis B therapy | - |
dc.subject | LB80380 | - |
dc.subject | Nucleotide analogue | - |
dc.subject | Resistance | - |
dc.subject | Viral suppression | - |
dc.subject.mesh | Adenine - Analogs & Derivatives - Therapeutic Use | en_US |
dc.subject.mesh | Alanine Transaminase - Blood | en_US |
dc.subject.mesh | Antiviral Agents - Therapeutic Use | en_US |
dc.subject.mesh | Dna, Viral - Blood | en_US |
dc.subject.mesh | Guanine - Adverse Effects - Analogs & Derivatives - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Hepatitis B E Antigens - Blood | en_US |
dc.subject.mesh | Hepatitis B, Chronic - Drug Therapy | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunologic Factors - Therapeutic Use | en_US |
dc.subject.mesh | Phosphonic Acids - Adverse Effects - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Practice Guidelines As Topic | en_US |
dc.title | LB80380: A promising new drug for the treatment of chronic Hepatitis B | en_US |
dc.type | Article | en_US |
dc.identifier.email | Fung, J:jfung@sicklehut.com | en_US |
dc.identifier.email | Lai, CL:hrmelcl@hku.hk | en_US |
dc.identifier.email | Yuen, MF:mfyuen@hkucc.hku.hk | en_US |
dc.identifier.authority | Fung, J=rp00518 | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.identifier.authority | Yuen, MF=rp00479 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1517/13543784.17.10.1581 | en_US |
dc.identifier.pmid | 18808318 | - |
dc.identifier.scopus | eid_2-s2.0-52949101763 | en_US |
dc.identifier.hkuros | 158453 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-52949101763&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 17 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.spage | 1581 | en_US |
dc.identifier.epage | 1588 | en_US |
dc.identifier.isi | WOS:000260080000016 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Fung, J=23091109300 | en_US |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_US |
dc.identifier.scopusauthorid | Yuen, MF=7102031955 | en_US |
dc.identifier.citeulike | 3353037 | - |
dc.identifier.issnl | 1354-3784 | - |